Sacubitril/valsartan as add-on to standard therapy in patients with heart failure: A randomized controlled trial
Reevanshi Dhawan, Rakesh Mittal, Ashwani Kumar, Kuldip S Laller, Paramjeet S Gill, Adarsh Rag, Niti Mittal
Reevanshi Dhawan, Rakesh Mittal, Adarsh Rag, Niti Mittal, Department of Pharmacology, PGIMS, Rohtak 124001, Haryana, India
Ashwani Kumar, Kuldip S Laller, Department of Cardiology, PGIMS, Rohtak 124001, Haryana, India
Paramjeet S Gill, Department of Microbiology, PGIMS, Rohtak 124001, Haryana, India
Co-first authors: Reevanshi Dhawan and Rakesh Mittal.
Author contributions: Dhawan R, Mittal R, Kumar A, Laller KS, Gill PS, Rag A, and Mittal N performed the conceptualization, data curation, data analysis, manuscript writing, and revision of the manuscript; the designation of two co-first authors is justified based on their equal and significant contributions to the conceptualization, execution, and communication of this study; all authors have played pivotal roles in guiding the research, analyzing data, and ensuring the manuscript's accuracy and completeness.
Institutional review board statement: This study was reviewed and approved by the Biomedical Research Ethics Committee of PGIMS, Rohtak, Haryana, No. BREC/23/TH-Pharma/01.
Clinical trial registration statement: The trial was registered prospectively with the clinical trials registry of India, No. CTRI/2023/07/055325.
Informed consent statement: All patients who participated in this study provided written informed consent.
Conflict-of-interest statement: All authors declare that they have no conflicts of interest to disclose.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Niti Mittal, Associate Professor, DM, Department of Pharmacology, PGIMS, Rohtak 124001, Haryana, India.
drnitimittal@uhsr.ac.in
Received: July 3, 2025
Revised: July 23, 2025
Accepted: October 27, 2025
Published online: December 20, 2025
Processing time: 170 Days and 1.5 Hours
